

ASX ANNOUNCEMENT

BENITEC BIOPHARMA (ASX: BLT; OTCPK: BTEBD)

22 July 2015

CHAIRMANS ADDRESS AND RESULTS OF THE GENERAL MEETING HELD ON WEDNESDAY 22 JULY 2015

Sydney, Australia

CHAIRMANS ADDRESS

“Ladies and gentlemen

Welcome to Benitec Biopharma’s General Meeting.

On behalf of my Board and all Benitec employees I would like to thank you for your continued support and for taking the time to attend today’s meeting.

The purpose of this morning’s General Meeting is to consider the resolution to approve the issue of new fully paid ordinary shares in the Company in connection with the Company’s proposed initial public offer in the United States and the associated listing on the NASDAQ Global Select Market.

The Company proposes to issue up to 115 million New Shares through the initial public offer, which would be represented by American Depositary Shares for trading on NASDAQ.

The Company proposes to raise approximately US\$60 - 70 million under the IPO, although the final amount to be raised and the number of New Shares to be issued will be determined by the Company in conjunction with the underwriters of the IPO. The Company intends to use the net proceeds of the IPO to advance the programs for its therapies, for working capital and for general corporate purposes.

I confirm that the directors of the Company unanimously recommend that you vote in favour of the Resolution.

I note that this resolution has currency for three months and we expect the offering process to be completed well within this time frame.”

Peter Francis
Chairman

RESULTS OF THE GENERAL MEETING

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolution and the proxies received for this morning's General Meeting.

Approval for Issue of Shares

The instructions given to validly appointed proxies in respect of the resolution were as follows:

| For | Against | Abstain | Proxy's discretion |
|------------|-----------|---------|--------------------|
| 39,236,134 | 1,078,469 | 28,997 | 339,080 |

The motion was carried as an ordinary resolution on a show of hands.

This announcement has been prepared for publication in Australia and may not be released in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been registered under the US Securities Act of 1933 and may not be offered or sold in the United States absent registration or in transactions exempt from registration under the US Securities Act and applicable US state securities laws. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer and that will contain detailed information about the issuer and management, as well as financial statements.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

| Company | Investor relations |
|---|--|
| Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com | Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au |

About Benitec Biopharma Limited:

Benitec Biopharma Limited is a biotechnology company (ASX: BLT; OTCPK: BTEBD), which has developed a patented gene silencing technology delivered by gene therapy, called DNA directed RNA interference (ddRNAi) that has the potential to produce 'one-shot' cures for a range of diseases. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's disease, chronic neuropathic pain and retinitis pigmentosa. For more information visit www.benitec.com